COMPASS Pathways plc
No SEC Form 4 filings for $CMPS in the last 30 days.
Compass Pathways (CMPS) shares rose about 16% in pre-market, targeting levels not seen in over two years. The move follows a Trump executive order to speed medical research and treatment access, plus FDA CDER leadership changes. Compass said the FDA granted COMP360 a National Priority Voucher for treatment-resistant depression, and Jefferies estimates 75% to 85% approval odds in FY26.
COMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 basic and diluted loss of $1.88 per share versus a $0.41 consensus estimate, a 358.5% miss, and a net loss of $253.8M. Shares rose 4.9% to $11.80. The company is advancing its psilocybin therapy program in Phase 3 trials, according to the report.
Compass Pathways (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said two Phase 3 trials for COMP360 in treatment-resistant depression showed rapid onset and benefit maintained through at least 6 months. The company is on track for an FDA rolling NDA completion in Q4, with commercial launch expected in H1 2027, subject to approval. Cash was $433 million at quarter end.
Over the past 7 days, alphai's AI scored 8 news stories mentioning CMPS (COMPASS Pathways plc). Coverage has skewed bullish: 7 bullish, 1 neutral, and 0 bearish.
Recent CMPS coverage spans earnings, technology and mergers & acquisitions.
Near-term upside bias if traders interpret the FDA CDER leadership shift as supportive for psychedelic drug review timelines.
The earnings miss is large, but the stock rose 4.9% to $11.80, implying investors are discounting near-term losses in favor of pipeline milestones.
New Phase 3 efficacy and safety highlights plus an on-track Q4 rolling NDA completion and 1H 2027 launch target can re-rate approval and commercialization odds.
The rally is tied to a stronger-than-feared cash runway plus an unchanged, potentially accelerated FDA review path for COMP360.
The article reinforces a near-term regulatory timeline (rolling NDA modules through Q4) and a potential 1H 2027 launch, supported by new Phase 3 efficacy and cash runway.
alphai scores every news story that mentions CMPS with an AI model for sentiment and relevance, and aggregates insider trades from COMPASS Pathways plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Compass Pathways (CMPS) shares rose about 16% in pre-market, targeting levels not seen in over two years. The move follows a Trump executive order to speed medical research and treatment access, plus FDA CDER leadership changes. Compass said the FDA granted COMP360 a National Priority Voucher for treatment-resistant depression, and Jefferies estimates 75% to 85% approval odds in FY26.
3 min readCOMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 basic and diluted loss of $1.88 per share versus a $0.41 consensus estimate, a 358.5% miss, and a net loss of $253.8M. Shares rose 4.9% to $11.80. The company is advancing its psilocybin therapy program in Phase 3 trials, according to the report.
3 min readCompass Pathways (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said two Phase 3 trials for COMP360 in treatment-resistant depression showed rapid onset and benefit maintained through at least 6 months. The company is on track for an FDA rolling NDA completion in Q4, with commercial launch expected in H1 2027, subject to approval. Cash was $433 million at quarter end.
7 min readCompass Pathways (CMPS) shares rose about 4.8% after it reported Q2 and first-half 2026 results. The company said it had $433 million cash as of June 30, 2026, enough to fund operations through 2028, and reaffirmed COMP360’s NDA submission in Q4 2026 and U.S. launch in H1 2027, subject to FDA/DEA actions.
3 min readCompass Pathways plc (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said its COMP360 psilocybin for treatment-resistant depression showed rapid onset and benefit through at least 6 months in two Phase 3 trials. The company is pursuing a rolling NDA with Q4 completion and expects launch in H1 2027, subject to FDA approval and DEA rescheduling. Cash was $433 million at quarter end.
7 min readCOMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights • Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, furt
7 min readCompass Pathways (CMPS) shares closed up 1% at $12.99 after choppy trading. The company reported positive 26-week data from a second late-stage COMP360 trial in treatment-resistant depression, citing rapid symptom relief and durability for at least six months, with generally mild side effects. Analysts reiterated Buy ratings and price targets, citing support for an FDA filing expected in Q4.
5 min readThe article says psychedelics are nearing their first commercial test for depression. It cites Positive Phase III results for Compass Pathways’ psilocybin therapy, putting it on a path toward FDA review, and notes large deals involving Eli Lilly and AbbVie. It also compares to Johnson & Johnson’s Spravato esketamine, highlighting operational and regulatory challenges for classic psychedelics.
5 min readEli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Ark Genomic Revolution ETF sold Atai shares and bought Compass Pathways shares. The article cites Jefferies estimates of $1-2 billion peak sales for Atai’s BPL-003 and notes Compass’s COMP360 phase 3 results and potential 2026 NDA timing.
6 min readEli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Atai’s lead drug BPL-003 is in phase 3 for treatment-resistant depression, with Jefferies estimating peak sales of $1 billion to $2 billion. The article also notes Ark Genomic Revolution ETF trading in Atai and Compass, and highlights regulatory changes affecting psychedelic reviews.
7 min read
